当前位置:首页 > English > pregnancy and family > General Health > FDA Warns About Asthma Drug, Xolair

FDA Warns About Asthma Drug, Xolair

来源:www.webmd.com 作者: 2007-2-22
336*280 ads

摘要: 21, 2007 -- The FDA is calling for a “black box“ label warning for the asthmaasthma drug Xolair, alerting users it can cause potentially life-threatening allergic reactions。The FDA issued the alert after reviewing 48 cases of anaphylaxis -- life-threatening allergic reactions -- submitted to t......



Feb. 21, 2007 -- The FDA is calling for a "black box" label warning for the asthmaasthma drug Xolair, alerting users it can cause potentially life-threatening allergic reactions.

The FDA issued the alert after reviewing 48 cases of anaphylaxis -- life-threatening allergic reactions -- submitted to the agency from June 2003, when Xolair was approved, through December 2005.

These cases included symptoms of bronchospasm (narrowing of airways), difficulty breathing, drop in blood pressure, fainting, hiveshives, and swelling of the throat or tongue.

Nearly 15% of the patients required hospitalization. No deaths were reported.

The drug, which is injected, is also known by the generic name omalizumab.

It is approved for use in asthma patients aged 12 and older who have moderate to severe persistent asthma, and who have tested positive for a perennial aerial allergen -- such as pollen, grass, or dust.

The drug is a secondary treatment, recommended for those whose symptoms have not been adequately controlled with inhaled steroids.

Delayed Reaction Possible

The FDA alert warns that patients can have a delayed reaction from two to 24 hours -- or longer -- after injection.

It adds that patients who have not reacted in the past can still develop anaphylaxis following a later dose.

In about 39,500 patients who took Xolair, the FDA says anaphylaxis occurred in at least 0.1% of those treated.

The drug is currently injected in a medical setting once every two or four weeks, depending on the patient, according to an email response from the FDA.

Now, the FDA is asking health care professionals who administer Xolair to observe patients for at least two hours after giving the injection and to be prepared to manage life-threatening anaphylaxis if it occurs.

Also, patients who take Xolair should be told of the possibility of a delayed reaction and be able to recognize the signs and symptoms of anaphylaxis, the FDA says in its alert.

Patients using Xolair should carry medical contact information and an epinephrine auto-injector (EpiPen). They should also be prepared to begin treatment on themselves while they seek immediate medical attention should anaphylaxis occur.

Xolair was the first biologic, or biotechnology product, developed to treat such allergy-related asthma when it was brought to the market in 2003.

At the time of the FDA review, Xolair's maker, Genentech, Inc., reported three cases of anaphylaxis among the 3,507 subjects given the drug in premarketing clinical trials. Two additional cases were not called anaphylaxis at that time, but meet the criteria now being used for the postmarketing cases, the FDA says.

The FDA said in its announcement today that its action is due to the nature of anaphylaxis reports after the drug reached market, including their life-threatening potential, their frequency, and the possibility of delayed onset.

In addition to the boxed warning -- the most serious type -- the FDA is asking Genentech to revise the Xolair label and provide a medication guide for patients to strengthen the existing warning for anaphylaxis. Genentech is a WebMD sponsor.


SOURCES: Press release, FDA. FDA Alert: "Omalizumab (marketed as Xolair) Information." FDA Alert: "Information for Healthcare Professionals, Omalizumab (for Subcutaneous Use) (marketed as Xolair)."


医学百科App—医学基础知识学习工具


页:
返回顶部】【打印本文】【放入收藏夹】【收藏到新浪】【发布评论



察看关于《FDA Warns About Asthma Drug, Xolair》的讨论


关闭

网站地图 | RSS订阅 | 图文 | 版权说明 | 友情链接
Copyright © 2008 39kf.com All rights reserved. 医源世界 版权所有
医源世界所刊载之内容一般仅用于教育目的。您从医源世界获取的信息不得直接用于诊断、治疗疾病或应对您的健康问题。如果您怀疑自己有健康问题,请直接咨询您的保健医生。医源世界、作者、编辑都将不负任何责任和义务。
本站内容来源于网络,转载仅为传播信息促进医药行业发展,如果我们的行为侵犯了您的权益,请及时与我们联系我们将在收到通知后妥善处理该部分内容
联系Email: